358 related articles for article (PubMed ID: 19067436)
1. Population pharmacokinetics of valproate in Mexican children with epilepsy.
Correa T; Rodríguez I; Romano S
Biopharm Drug Dispos; 2008 Dec; 29(9):511-20. PubMed ID: 19067436
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
Jankovic SM; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients.
Jankovic SM; Jovanovic D; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2008 Nov; 30(9):707-13. PubMed ID: 19229380
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of valproate in Chinese children with epilepsy.
Jiang DC; Wang L; Wang YQ; Li L; Lu W; Bai XR
Acta Pharmacol Sin; 2007 Oct; 28(10):1677-84. PubMed ID: 17883957
[TBL] [Abstract][Full Text] [Related]
5. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data.
Fattore C; Messina S; Battino D; Croci D; Mamoli D; Perucca E
Epilepsy Res; 2006 Aug; 70(2-3):153-60. PubMed ID: 16730950
[TBL] [Abstract][Full Text] [Related]
6. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
7. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
[TBL] [Abstract][Full Text] [Related]
8. [Population pharmacokinetics of carbamazepine in adults with epilepsy].
Romano-Moreno S; Medina-Rojas EL; Salas-Ortiz AL; Vargas-Morales JM; Pérez-Urizar JT; Rodríguez-Leyva I
Rev Invest Clin; 2005; 57(1):38-48. PubMed ID: 15981957
[TBL] [Abstract][Full Text] [Related]
9. The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling.
Vucićević K; Miljković B; Pokrajac M; Prostran M; Martinović Z; Grabnar I
Eur J Pharm Sci; 2009 Dec; 38(5):512-8. PubMed ID: 19804822
[TBL] [Abstract][Full Text] [Related]
10. Valproate population pharmacokinetics in children.
Serrano BB; García Sánchez MJ; Otero MJ; Buelga DS; Serrano J; Domínguez-Gil A
J Clin Pharm Ther; 1999 Feb; 24(1):73-80. PubMed ID: 10319910
[TBL] [Abstract][Full Text] [Related]
11. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy.
Dutta S; Faught E; Limdi NA
J Clin Pharm Ther; 2007 Aug; 32(4):365-71. PubMed ID: 17635338
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid clearance in children with epilepsy.
Sánchez-Alcaraz A; Quintana MB; López E; Rodríguez I
J Clin Pharm Ther; 1998 Feb; 23(1):31-4. PubMed ID: 9756109
[TBL] [Abstract][Full Text] [Related]
13. Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children.
Ueshima S; Aiba T; Makita T; Nishihara S; Kitamura Y; Kurosaki Y; Kawasaki H; Sendo T; Ohtsuka Y; Gomita Y
J Clin Pharm Ther; 2008 Feb; 33(1):31-8. PubMed ID: 18211614
[TBL] [Abstract][Full Text] [Related]
14. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data.
Blanco-Serrano B; Otero MJ; Santos-Buelga D; García-Sánchez MJ; Serrano J; Domínguez-Gil A
Biopharm Drug Dispos; 1999 Jul; 20(5):233-40. PubMed ID: 10594867
[TBL] [Abstract][Full Text] [Related]
15. Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data.
Messina S; Battino D; Croci D; Mamoli D; Ratti S; Perucca E
Epilepsia; 2005 Mar; 46(3):372-7. PubMed ID: 15730534
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing valproate pharmacokinetics in children and adults.
Jankovic SM; Milovanovic JR; Jankovic S
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):767-75. PubMed ID: 20979937
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication.
May TW; Boor R; Rambeck B; Jürgens U; Korn-Merker E; Brandt C
Ther Drug Monit; 2011 Apr; 33(2):214-21. PubMed ID: 21383651
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
[TBL] [Abstract][Full Text] [Related]
19. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
Yukawa E; Honda T; Ohdo S; Higuchi S; Aoyama T
J Pharm Pharmacol; 1997 Aug; 49(8):751-6. PubMed ID: 9379350
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy.
Rivas N; Buelga DS; Elger CE; Santos-Borbujo J; Otero MJ; Domínguez-Gil A; García MJ
Ther Drug Monit; 2008 Aug; 30(4):483-9. PubMed ID: 18641550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
